Procedural steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 February2004 please refer to module 8B. 
Scope 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
13.02.02 
Commission 
Decision 
Issued/amen
ded on 
06.03.02 
08.04.02 
11.04.02 
08.04.02 
11.04.02 
08.04.02 
11.04.02 
06.08.02 
30.08.02 
I-0001 
I-0002 
I-0003 
I-0004 
I-0005 
I 
I 
I 
I 
I 
II-0006 
II 
19.09.02 
05.12.02 
II-0007 
II 
20.02.03 
19.05.03 
II-0008 
II 
20.02.03 
19.05.03 
II-0009 
II 
20.02.03 
19.05.03 
On 8 February 2002 the Marketing Authorisation Holder (MAH) 
applied for a change in or addition of manufacturing site(s) for part 
or all of the manufacturing process. 
On 14 March 2002 the MAH applied for a change in the batch size 
of finished product. 
On 14 March 2002 the MAH applied for minor changes in 
manufacture of the medicinal product. 
On 14 March 2002 the MAH applied for minor changes in 
manufacture of the medicinal product. 
On 01 July 2002 the MAH applied for a change in or addition of 
manufacturing site(s) for part or all of the manufacturing process. 
On 16 July 2002 the MAH applied for changes of section 4.4 
(Special warnings and special precautions for use) and 4.5 
(Interaction with other medicinal products and other forms of 
interaction) of the Summary of Products Characteristics (SPC) as 
well as the corresponding relevant sections of the Package Leaflet 
(PL) of Viread 245 mg film-coated tablets, further to the CPMP 
assessment of the results of the pharmacokinetic study (GS-01-932), 
which evaluated the effect of tenofovir disoproxil fumarate (TDF) 
on the pharmacokinetics of didanosine following concomitant use of 
Viread tablets and Videx EC 400 mg gastro-resistant capsules. 
Moreover, the MAH proposed some minor linguistic corrections of 
the language versions of the SPC and the Package Leaflet (PL). 
On 3 September 2002, the MAH applied to update the SPC and the 
relevant sections of the PL with regard to safety of TDF based on 
long term data of clinical studies supplied and on data assessed in 
the first Periodic Safety Update Report (31/10/02 - 30/04/02): 
- Inclusion, in Section 4.4 (Special warnings and special precautions 
for use), of warning statements with regard to renal and bone 
toxicity and amendment of the information on concomitant use of 
nephrotoxic medicinal products and of the recommendation for 
monitoring of serum creatinine and serum phosphorus. 
- Inclusion, in section 4.5 (Interaction with other medicinal products 
and other forms of interaction), of minor wording changes. 
- In Section 4.6 (Pregnancy and lactation), information with regard 
to the establishment of a pregnancy register is provided. 
- Amendment, in section 4.8 (Undesirable effects), of the 
information on experience from pivotal clinical trials and inclusion 
of experience from Post Marketing Surveillance. 
On 3 September 2002, the MAH applied to extend the indication of 
TDF to include the initial therapy of HIV-1 infection in treatment 
naïve adults. Moreover, the MAH proposed to amend section 5.1 
(Pharmacodynamic properties) in order to update the ATC code and 
the final 48-weeks data of clinical studies. 
The MAH took also the opportunity to update section 4.4 (Special 
warning and precautions for use) and 5.3 (Preclinical safety data) in 
line with the assessment of the safety data submitted. 
On 3 September 2002, the MAH applied to include dosage 
guidelines for patients with renal impairment in section 4.2 
(Posology and method of administration) based on the results of the 
new clinical study, aimed at evaluating the pharmacokinetics of TDF 
in subjects with normal and impaired renal function.  
Amendments in section 4.3 (contraindication), 4.4 (Special warnings 
and special precautions for use) and 5.2 (Pharmacokinetic 
properties) are also proposed and an update of the Package Leaflet 
(PL), section 2 (Before you take Viread) in accordance with SPC 
changes. 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I 
variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 
8 of the Regulation; X refers to an Annex II application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
S refers to an annual reassessment. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision 
will be amended accordingly. 
1/3 
EMEA 2005 
 
 
                                                      
On 3 September 2002, the MAH applied for changes of section 5.3  
(Preclinical Safety Data, third paragraph only on genotoxicity 
studies) of the SPC of Viread 245 mg film-coated tablets, further to 
the CPMP assessment of the results of the in vivo/in vitro 
unscheduled DNA synthesis test and the availability of the 
preliminary histopathology data from the rat carcinogenicity study. 
On 4 November 2002 the MAH applied for a change in or addition 
of manufacturing site(s) for part or all of the manufacturing process. 
On 22 November 2002 the MAH applied for minor changes in the 
labelling and addition in the PL of the local representatives of the 
MAH not connected to the SPC. 
On 23 December 2003 the MAH applied for changes of section 4.2. 
(Posology and method of administration) of the SPC of Viread 245 
mg film-coated tablets and corresponding section 3 (How to take 
your medicine) of the PL, further to the CPMP assessment of a 
follow-up measure concerning the feasibility of patients 
disintegrating the tablets in liquids for ingestion by drinking.  
The MAH took this opportunity to make a slight typographical 
amendment to the dosage recommendation for patients with renal 
impairment. 
On 23 December 2003 the MAH applied for a type II variation to 
include in section 4.4 (Special warning and precautions for use) of 
the SPC, a class labelling statement with respect to lactic acidosis 
further to the request of the CPMP as a result of the assessment of 
the first PSUR (covering the time period 31/10/01-30/04/02). 
Relevant changes have also been implemented in the PL. 
On 23 December 2003 the MAH applied for a type II variation to 
include in section 5.1 (Pharmacodynamic properties) of the SPC a 
precautionary measure regarding the deleterious effect of the M41L 
and L210W mutations.  
On 14 January 2003 the MAH applied for a change in or addition of 
manufacturing site(s) for part or all of the manufacturing process. 
On 14 January 2003 the MAH applied for a change in or addition of 
manufacturing site(s) for part or all of the manufacturing process. 
On 24 February 2003 the MAH applied for an update of sections 4.4 
(Special warnings and special precautions for use), 4.5 (Interaction 
with other medicinal products and other forms of interaction) and 
5.2 (Pharmacokinetic Properties) of the Summary of Product 
Characteristics (SPC) concerning data provided from studies that 
investigate the concomitant use of Viread and a reduced dose of 
didanosine, as well as studies of potential interactions with 
methadone and a combined estrogen/progestin oral contraceptive.  
Relevant changes are equally proposed for the PL 
On 11 February 2003 the MAH applied for an update of the SPC to 
include the class labelling on Lipodystrophy in sections 4.4  
(“ Special warnings and special precautions for use”) and 4.8 
(“Undesirable Effects”). Relevant changes are equally proposed for 
the PL. 
On 24 April 2003 the MAH applied for a change in the name of a 
manufacturer of the medicinal product. 
On 24 April 2003 the MAH applied for a change in the name of a 
manufacturer of the medicinal product. 
On 10 June 2003 the MAH applied for a minor change of 
manufacturing process of the active substance. 
On 10 June 2003 the MAH applied for a minor change of 
manufacturing process of the active substance. 
On 10 June 2003 the MAH applied for a minor change of 
manufacturing process of the active substance. 
On 10 June 2003 the MAH applied for a minor change of 
manufacturing process of the active substance. 
On 10 June 2003 the MAH applied for a minor change of 
manufacturing process of the active substance. 
Annual reassessment  
On 2 July 2003 the MAH applied to amend section 4.8 (Undesirable 
effects) of the SPC of Viread 245 mg film-coated tablets to 
incorporate the additional adverse drug reaction of “acute renal 
failure” and “proteinuria” in the post-marketing experience 
information. This variation also aims to modify this same section to 
use MedDRA System Organ Class headings rather than the 
COSTART Body system headings currently used as requested by the 
CPMP further to the assessment of variation EMEA/H/C/419/II/07. 
On 3 July 2003 the MAH applied for an update of the section 4.2 
(Posology and method of administration), section 4.4 (Special 
warnings and special precautions of use) and 5.2 (Pharmacokinetic 
properties) of the SPC of Viread 245 mg film-coated tablets to 
implement the class labelling on liver impairment adopted by the 
CPMP for all anti-retroviral medicinal products on 25 April 2003.  
II-10 
II 
21.11.02 
27.03.03 
I-0011 
N-0012 
II-0013 
I 
N 
II 
10.12.02 
12.12.02 
Corrigendum
06.02.03 
- 
19.03.03 
09.07.03 
II-0014 
II 
19.03.03 
09.07.03 
II-0015 
I-0016 
I-0017 
II-0018 
II 
I 
I 
II 
19.03.03 
09.07.03 
22.02.03 
04.03.03 
22.02.03 
04.03.03 
24.07.03 
20.10.03 
II-0019 
II 
19.03.03 
10.07.03 
I-0021 
I-0022 
I-0023 
I-0025 
I-0026 
I-0027 
I-0028 
S-0020 
II-0029 
I 
I 
I 
I 
I 
I 
I 
S 
II 
31.05.03 
09.07.03 
31.05.03 
11.06.03 
09.07.03 
17.07.03 
09.07.03 
17.07.03 
09.07.03 
17.07.03 
09.07.03 
17.07.03 
09.07.03 
17.07.03 
25.04.03 
25.09.03 
01.08.03 
14.01.04 
II-0030 
II 
20.11.03 
30.01.04 
2/3 
EMEA 2005 
 
In addition, the MAH proposes changes to sections 5.2 and 4.2, 
based on pharmacokinetic data from the final Study report in non-
infected subjects with either normal hepatic function or varying 
degrees of hepatic impairment, as well as the inclusion, in section 
4.4, of a warning regarding the potential risk of hepatitis flares 
following discontinuation of Viread in patients co-infected with 
hepatitis B. 
Changes to the Package Leaflet (PL) in accordance with the 
proposed changes to the SPC have also been proposed. 
On 21 July 2003 the MAH applied for a change in or addition of 
manufacturer(s) of active substance 
On 15 September 2003 the MAH applied for an update to section 5.3 
(Preclinical safety data) of the SPC of Viread 245 mg film-coated 
tablets in view of the results obtained from long-term 
carcinogenicity studies in the rat and mouse. The submission of this 
final report was requested by the CPMP, as Specific Obligation 
stated in the MAH’s letter of undertaking dated 17 October 2001.  
I-0031 
II-0032 
I 
II 
22.08.03 
- 
20.11.03 
30.01.04 
3/3 
EMEA 2005 
 
 
 
 
 
